Figure 3

6B12 antibody suppresses primary tumor and lung metastasis development and inhibits T-lymphocyte attraction in the PyMT model. (A) Primary tumor growth of PyMT mice treated with 6B12 (n = 15) or IgG control (n = 21). (B) Upper panel: Representative images of blood vessel density in the tumor tissue sections from tumor-bearing mice treated with 6B12 and IgG (immunostaining with anti-CD31 antibody. Bar, 50 μm. Lower panel: Vessel density of primary tumors developed in PyMT mice treated with 6B12 (n = 6) or IgG control (n = 9). (C) Upper panel: Representative images of tumor tissue sections from 12 week-old PyMT mice treated with 6B12 antibody or with IgG control stained with anti-CD3 antibody. Bar, 50 μm. Lower panel: Quantification of CD3+ T-lymphocytes in the vicinity of primary tumor lesions from 12-week-old PyMT mice treated with 6B12 (n = 5) or IgG control (n = 8). (D) Metastatic burden in the lungs of PyMT mice treated with 6B12 (n = 15) or IgG control (n = 21). (E) Number of metastatic foci per lung per mouse in PyMT mice treated with 6B12 or IgG control.